The NAD+ shelf is crowded, the labels all look alike, and the regulatory ground underneath it has moved twice in three years. Here is how to choose an ingredient form, check the serving arithmetic before you print, and confirm the compliance position for your own market.
TL;DR
Short answer: The broader NAD-related products market is estimated near $4.5B in 2026, growing around 15% a year. “NAD+” on a front label can mean four different ingredients, and the specific form — not the category name — decides your regulatory risk and your cost. Intact NAD+ is a dinucleotide and is degraded in the digestive tract, so verify the delivery claim and re-check the regulatory position before printing a label.
Published market research puts the NAD-related products market at roughly $3.9B in 2025, about $4.5B in 2026, and near $12.2B by 2033 — a compound growth rate in the mid-teens. Different research houses draw the category boundary differently, so treat the exact figure as directional. What every source agrees on is double-digit growth for the rest of the decade, and that direction — not the decimal — is what justifies opening a SKU.
The same speed that makes the category attractive is what makes it dangerous. Ingredient forms move in and out of regulatory scope, marketing copy runs ahead of the evidence, and the products already on shelf are not always what the label claims. The rest of this guide is about closing that gap on your side of the table, before your brand is the one carrying the risk.
Market sizing as reported by published industry research for 2025–2026. Figures are indicative and category scope varies by source — verify current numbers before building a business case on them.
The word on the front panel is not the ingredient. Before you compare a single price, ask for the specification sheet: chemical name, CAS number, and the assay method the factory uses to measure it. Two quotes that both say “NAD+” can describe two different molecules at two different cost levels.
| Ingredient form | What it actually is | Typical formats | What it changes for you |
|---|---|---|---|
| NAD+ (nicotinamide adenine dinucleotide) | The intact coenzyme; a dinucleotide | Capsules, softgels, sublingual, powder | Strongest longevity story and the highest input cost. The weak point is oral stability, so the delivery system has to be substantiated. |
| NMN (beta-nicotinamide mononucleotide) | A direct NAD+ precursor, one step upstream | Capsules, powder, sublingual | The most-discussed form in the US, and the one whose regulatory status has moved. Verify it every single time. |
| NR (nicotinamide riboside) | Another NAD+ precursor | Capsules | A longer-standing presence on US shelves. Ask for the specific supplier's documentation rather than assuming parity. |
| Niacin, niacinamide, NADH | Related B3-family or reduced forms | Tablets, capsules | Cheapest inputs, different claim set, different buyer. Do not let a supplier quote one of these against an NAD+ brief. |
The mismatch that quietly costs brands money
A supplier quotes an attractive price on “NAD+” and ships a niacinamide blend. The two are not interchangeable, and the finished label cannot legally imply that they are. Match every quotation to a chemical name, a CAS number and an assay method — that single discipline removes most of the risk in this category.
NAD+ is a dinucleotide — large, charged, and poorly suited to surviving the digestive tract intact. That one fact explains almost every formulation decision in the category. Manufacturers either use a precursor the body converts, or they wrap the NAD+ itself in a system designed to get more of it through.
Ask for the encapsulation data, not the word
Any supplier can print “liposomal”. Ask for the properties that make the claim real: encapsulation efficiency, particle size distribution, and a stability study on the finished product. A factory that has the data will send it in the first reply. A factory that does not will send a brochure. If you cannot substantiate the delivery claim, do not put it on the label — you still have a legitimate product, just a differently positioned one.
Most disputes in this category are arithmetic, not chemistry. Four numbers have to agree with each other, and the trap is the word “total”.
Worked example: a formula of liposomal NAD+ 1,200mg plus trans-resveratrol 300mg per serving, at two capsules per serving and 90 capsules per bottle, delivers 1,500mg across two actives and 45 servings per bottle. The front panel may say 1,500mg per serving; the panel inside must name both actives, and nothing anywhere should read as 1,500mg of NAD+ alone.
This is the section to read twice. The US status of the best-known NAD+ precursor has changed twice in three years, which means any published summary — this one included — is a snapshot, not a clearance.
An NDI notification is not an approval of the ingredient
It is a notifier-specific safety conclusion for a defined production process under specific conditions of use. Do not read it as a blanket green light for every version or dose of the molecule — and never present it to a customer as a certification you hold.
For most brands entering the category, a capsule is the right first SKU. It carries a multi-active formula cleanly, travels well, and lets you keep the delivery claim optional until you have the data to make it. Extend into a second format only after the first one sells through — that is when a trend becomes a line.
Is NAD+ legal to sell as a dietary supplement in the US?
No supplement is “FDA approved” — that category does not exist for dietary supplements. The real question is whether a specific ingredient form is excluded from the dietary supplement definition, and for the best-known NAD+ precursor that answer has changed twice since 2022: the FDA excluded beta-NMN in November 2022, then confirmed in a September 2025 letter that it is not excluded, reopening the New Dietary Ingredient pathway. Treat any published answer, including this one, as a snapshot and verify the current position for your exact form and market before printing.
What is the difference between NAD+, NMN and NR?
NAD+ is the intact coenzyme; NMN and NR are precursors, smaller molecules the body converts toward NAD+. They are not interchangeable on a label — each has its own chemical identity, regulatory history and input cost. Always match a quotation to a chemical name and a CAS number before you compare prices.
Does a liposomal NAD+ capsule really absorb better?
The rationale is sound. Intact NAD+ is a dinucleotide and is degraded in the digestive tract, so enclosing it in lipid vesicles is a legitimate attempt to protect it through digestion. Whether a specific product delivers on that promise depends on the actual encapsulation, not the marketing term. Ask for encapsulation efficiency, particle size distribution and finished-product stability data.
What dose should I put on my label?
There is no single industry-standard dose, and you should be cautious with a factory that offers one without discussion. Agree a target dose per serving, confirm what is measured after manufacturing, label each active separately on the Supplement Facts panel, and make sure the serving size in pieces matches the arithmetic you advertise.
Can I market an NAD+ product as anti-ageing?
Not with disease or drug-like claims. Keep to structure/function language, add the standard FDA disclaimer, and be ready to substantiate every statement you make. Language such as supporting cellular energy metabolism is the kind of claim a well-documented product can carry; anything that reads like treating or preventing a condition is not.
What is the minimum order for an NAD+ private label product?
Our stocked liposomal NAD+ and trans-resveratrol capsule starts at a 200-bottle entry tier, with a lower unit price at 1,000+ bottles; custom formula development is quoted on its own tier. Ask for the current specification and tier sheet rather than assuming from the category.
Our liposomal Resveratrol + NAD+ capsule is stocked at 1,500mg per serving — 1,200mg NAD+ plus 300mg trans-resveratrol across 2 capsules, 90 capsules per bottle — with real entry tiers. Send an RFQ and we will return the specification, the serving arithmetic and the documentation your market needs.